Purinergic regulation of vascular endothelial growth factor signaling in angiogenesis

被引:47
作者
Rumjahn, S. M. [1 ]
Yokdang, N. [1 ]
Baldwin, K. A. [1 ]
Thai, J. [1 ]
Buxton, I. L. O. [1 ]
机构
[1] Univ Nevada, Sch Med, Dept Pharmacol, Reno, NV 89557 USA
关键词
breast cancer; angiogenesis; purinergic receptor; P2Y; VEGF; VEGFR2; phosphotyrosine; NUCLEOSIDE DIPHOSPHATE KINASE; ADHESION MOLECULE-1 EXPRESSION; VEGF RECEPTOR-2; CELLULAR MIGRATION; P2; RECEPTORS; HUMAN BREAST; CELLS; MICE; PERMEABILITY; CANCER;
D O I
10.1038/sj.bjc.6604998
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
P2Y purine nucleotide receptors (P2YRs) promote endothelial cell tubulogenesis through breast cancer cell-secreted nucleoside diphosphate kinase (NDPK). We tested the hypothesis that activated P2Y(1) receptors transactivate vascular endothelial growth factor receptor (VEGFR-2) in angiogenic signaling. P2Y(1)R stimulation (10 mu M 2-methyl-thio-ATP (2MS-ATP)) of angiogenesis is suppressed by the VEGFR-2 tyrosine kinase inhibitor, SU1498 (1 mu M). Phosphorylation of VEGFR-2 by 0.0262 or 2.62 nM VEGF was comparable with 0.01 or 10 mu M 2MS-ATP stimulation of the P2Y(1)R. 2MS-ATP, and VEGF stimulation increased tyrosine phosphorylation at tyr1175. 2MS-ATP (0.1-10 mu M) also stimulated EC tubulogenesis in a dose-dependent manner. The addition of sub-maximal VEGF (70 pM) in the presence of increasing concentrations of 2MS-ATP yielded additive effects at 2MS-ATP concentrations <3 mu M, whereas producing saturated and less than additive effects at >= 3 mu M. We propose that the VEGF receptor can be activated in the absence of VEGF, and that the P2YR-VEGFR2 interaction and resulting signal transduction is a critical determinant of vascular homoeostasis and tumour-mediated angiogenesis.
引用
收藏
页码:1465 / 1470
页数:6
相关论文
共 27 条
[1]  
Anzinger J, 2001, P W PHARMACOL SOC, V44, P61
[2]   Role of tyrosine kinase inhibitors in cancer therapy [J].
Arora, A ;
Scholar, EM .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2005, 315 (03) :971-979
[3]   Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal [J].
Benjamin, LE ;
Golijanin, D ;
Itin, A ;
Pode, D ;
Keshet, E .
JOURNAL OF CLINICAL INVESTIGATION, 1999, 103 (02) :159-165
[4]   Pathophysiology and therapeutic potential of purinergic signaling [J].
Burnstock, G .
PHARMACOLOGICAL REVIEWS, 2006, 58 (01) :58-86
[5]   Evidence supporting the Nucleotide Axis Hypothesis: ATP release and metabolism by coronary endothelium [J].
Buxton, ILO ;
Kaiser, RA ;
Oxhorn, BC ;
Cheek, DJ .
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 2001, 281 (04) :H1657-H1666
[6]   Cytotoxic activity of nucleoside diphosphate kinase secreted from Mycobacterium tuberculosis [J].
Chopra, P ;
Singh, A ;
Koul, A ;
Ramachandran, S ;
Drlica, K ;
Tyagi, AK ;
Singh, Y .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 2003, 270 (04) :625-634
[7]   P2 receptors in cardiovascular regulation and disease [J].
Erlinge, David ;
Burnstock, Geoffrey .
PURINERGIC SIGNALLING, 2008, 4 (01) :1-20
[8]   Intrinsic tyrosine kinase activity is required for vascular endothelial growth factor receptor 2 ubiquitination, sorting and degradation in endothelial cells [J].
Ewan, Lorna C. ;
Jopling, Helen M. ;
Jia, Haiyan ;
Mittar, Shweta ;
Bagherzadeh, Azadeh ;
Howell, Gareth J. ;
Walker, John H. ;
Zachary, Ian C. ;
Ponnambalam, Sreenivasan .
TRAFFIC, 2006, 7 (09) :1270-1282
[9]   Disordered cellular migration and angiogenesis in cd39-null mice [J].
Goepfert, C ;
Sundberg, C ;
Sévigny, J ;
Enjyoji, K ;
Hoshi, T ;
Csizmadia, E ;
Robson, S .
CIRCULATION, 2001, 104 (25) :3109-3115
[10]   Secreted variant of nucleoside diphosphate kinase from the intracellular parasitic nematode Trichinella spiralis [J].
Gounaris, K ;
Thomas, S ;
Najarro, P ;
Selkirk, ME .
INFECTION AND IMMUNITY, 2001, 69 (06) :3658-3662